ATE485055T1 - Adjuvierte antigene meningokokkenzusammensetzungen - Google Patents

Adjuvierte antigene meningokokkenzusammensetzungen

Info

Publication number
ATE485055T1
ATE485055T1 AT02788442T AT02788442T ATE485055T1 AT E485055 T1 ATE485055 T1 AT E485055T1 AT 02788442 T AT02788442 T AT 02788442T AT 02788442 T AT02788442 T AT 02788442T AT E485055 T1 ATE485055 T1 AT E485055T1
Authority
AT
Austria
Prior art keywords
adjuved
antigen
meningococcal
compositions
meningococcal compositions
Prior art date
Application number
AT02788442T
Other languages
German (de)
English (en)
Inventor
Mariagrazia Pizza
Marzia Giuliani
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE485055T1 publication Critical patent/ATE485055T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02788442T 2001-12-04 2002-12-04 Adjuvierte antigene meningokokkenzusammensetzungen ATE485055T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0129007.1A GB0129007D0 (en) 2001-12-04 2001-12-04 Adjuvanted antigenic meningococcal compositions
PCT/IB2002/005662 WO2003047619A2 (en) 2001-12-04 2002-12-04 Adjuvanted antigenic meningococcal compositions

Publications (1)

Publication Number Publication Date
ATE485055T1 true ATE485055T1 (de) 2010-11-15

Family

ID=9926977

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02788442T ATE485055T1 (de) 2001-12-04 2002-12-04 Adjuvierte antigene meningokokkenzusammensetzungen

Country Status (11)

Country Link
US (2) US20060008476A1 (enExample)
EP (1) EP1448230B1 (enExample)
JP (2) JP4414226B2 (enExample)
AP (1) AP2004003074A0 (enExample)
AT (1) ATE485055T1 (enExample)
AU (1) AU2002353417A1 (enExample)
CA (1) CA2468935C (enExample)
CY (1) CY1111114T1 (enExample)
DE (1) DE60238075D1 (enExample)
GB (1) GB0129007D0 (enExample)
WO (1) WO2003047619A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9513371D0 (en) * 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
DE60144353D1 (de) * 2000-02-28 2011-05-12 Novartis Vaccines & Diagnostic Hybride Expression Neisserscher Proteine
CN1977971A (zh) * 2001-06-07 2007-06-13 惠氏控股有限公司 作为佐剂的霍乱全毒素的突变体形式
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
EP1506007B1 (en) * 2002-05-14 2011-06-22 Novartis Vaccines and Diagnostics S.r.l. Mucosal combination vaccines for bacterial meningitis
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
EP1961426B1 (en) 2003-10-02 2011-04-27 Novartis Vaccines and Diagnostics S.r.l. Combined meningitis vaccines
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
CA2756522C (en) 2009-03-24 2018-06-26 Novartis Ag Adjuvanting meningococcal factor h binding protein
SI3831406T1 (sl) 2010-08-23 2024-08-30 Wyeth Llc Stabilne formulacije antigenov neisseria meningitidis RLP2086
NZ607224A (en) 2010-09-10 2014-11-28 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
US20130287808A1 (en) * 2010-11-05 2013-10-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vaccines for preventing meningococcal infections
GB201102090D0 (en) * 2011-02-08 2011-03-23 Univ Sheffield Antigenic polypeptide
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
RU2665841C2 (ru) 2012-03-09 2018-09-04 Пфайзер Инк. Композиции neisseria meningitidis и способы их применения
EP2877492A1 (en) 2012-07-27 2015-06-03 Institut National de la Santé et de la Recherche Médicale (INSERM) Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
EP2964665B1 (en) 2013-03-08 2018-08-01 Pfizer Inc Immunogenic fusion polypeptides
BR112016004463A2 (pt) 2013-09-08 2017-10-17 Pfizer composições de neisseria meningitidis e métodos das mesmas
US10888611B2 (en) 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN118021947A (zh) 2017-01-31 2024-05-14 辉瑞大药厂 脑膜炎奈瑟菌组合物及其使用方法
MX2021007539A (es) * 2018-12-21 2021-09-21 Univ Griffith Composiciones, metodos y usos para provocar una respuesta inmune.
MX2022003682A (es) 2019-09-27 2022-04-25 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
US20220348645A1 (en) * 2019-10-01 2022-11-03 Beth Israel Deaconess Medical Center, Inc. Conformation-specific antibodies that bind nuclear factor kappa-light-chain-enhancer of activated b cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2671261A1 (en) * 1997-11-06 1999-05-20 Novartis Vaccines And Diagnostics S.R.L. Neisserial antigens
GB9726398D0 (en) * 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
BR9906927A (pt) * 1998-01-14 2001-11-20 Chiron Spa Proteìnas de neisseria meningitidis
PT1117435E (pt) * 1998-09-30 2008-02-21 Us Gov Univ Health Sciences Holotoxina da cólera mutante como adjuvante
US7384640B1 (en) * 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.

Also Published As

Publication number Publication date
US20100233205A1 (en) 2010-09-16
US20060008476A1 (en) 2006-01-12
JP2005511662A (ja) 2005-04-28
GB0129007D0 (en) 2002-01-23
CY1111114T1 (el) 2015-06-11
EP1448230A2 (en) 2004-08-25
AU2002353417A1 (en) 2003-06-17
WO2003047619A3 (en) 2003-10-23
EP1448230B1 (en) 2010-10-20
CA2468935A1 (en) 2003-06-12
CA2468935C (en) 2013-02-05
DE60238075D1 (de) 2010-12-02
WO2003047619A2 (en) 2003-06-12
AP2004003074A0 (en) 2004-06-30
JP2009155344A (ja) 2009-07-16
JP4414226B2 (ja) 2010-02-10

Similar Documents

Publication Publication Date Title
ATE485055T1 (de) Adjuvierte antigene meningokokkenzusammensetzungen
ATE553775T1 (de) Impstoffzusammesetzung
FI20010780A0 (fi) Parannetut koostumukset
NO20026175L (no) Vaksinesammensetning
PL368370A1 (pl) Kompozycja glifosatu
AR028197A1 (es) Composiciones antitranspirantes
IS6915A (is) Lyfjablanda
IS7297A (is) Streptococcis Pneumoniae bóluefni
BR0210619A (pt) composição
IS7081A (is) Lyfjablanda
NO20033882L (no) Vaksine
DE60205322D1 (de) Fluoroelastomere
EE200300569A (et) CD44v6-spetsiifilised antikehad
DE60229463D1 (de) Fluoroelastomere
EE200300480A (et) Pregabaliini-laktoosi konjugaadid
EP1420818A4 (en) ANTIGENIC COMPOSITIONS
DE50202942D1 (de) Basenhältige mikronährstoffmischung
DE50206933D1 (de) Zweimassenschwungrad
EP1313839A4 (en) IMMUNE SYSTEM INCREASING COMPOSITIONS
EP1454914A4 (en) TUMOR ANTIGEN
DE60213119D1 (de) Zweimassenschwungrad
ITTO20020747A0 (it) Composizione
DE50100362D1 (de) Kreuzscheibenkupplung
DE60217632D1 (de) Wandnachbildungen
EE200300377A (et) Loomulikud HI-viiruse vastased antikehad

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties